Amgen: favourable court ruling against Sandoz
(CercleFinance.com) - Sandoz has announced an unfavourable court ruling from the District Court of New Jersey in the US in a patent dispute regarding its Erelzi (etanercept-szzs) for Amgen's reference drug Enbrel (etanercept).
"Ruling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases," said Novartis' generic subsidiary.
Novartis intends to appeal against the decision in a court of appeal, with both parties having agreed on an accelerated appeal. Erelzi was approved nearly three years ago, but could not be launched because of the patent dispute with Amgen.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
"Ruling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases," said Novartis' generic subsidiary.
Novartis intends to appeal against the decision in a court of appeal, with both parties having agreed on an accelerated appeal. Erelzi was approved nearly three years ago, but could not be launched because of the patent dispute with Amgen.
Copyright (c) 2019 CercleFinance.com. All rights reserved.